PROTACPARP1 degrader is a degrader of PARP1 based on the PROTAC technology. PROTACPARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line (IC50 of 6.12 μM).
NH2-PEG7 is a para-aminomethylbenzyloxycarbonyl (PROTAC) linker compound consisting of a polyethylene glycol (PEG) chain. It finds application in the synthesis of the PROTACPARP1 degrader called iRucaparib-AP6[1].
iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1. iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach.
Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker designed for use in antibody-drug conjugates (ADCs). This compound can be coupled to a protein ligand via a linker to create PROTAC iRucaparib-AP6, an extremely selective degrader of PARP1[1].
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate combining the (S,R,S)-AHPC-based VHL ligand with a 4-unit polyethylene glycol (PEG) linker, employed in PROteolysis TAgeting Chimera (PROTAC) technology. This compound facilitates the creation of vRucaparib-TP4, a potent PARP1 degrader demonstrating a half-maximal degrading concentration (DC50) of 82 nM[1].